Acasti Pharma Inc.’s Acquisition of Grace Therapeutics

Osler, Hoskin & Harcourt LLP advised Acasti Pharma on the deal, while Reed Smith advised Grace Therapeutics.

Acasti Pharma entered into of a definitive agreement to acquire Grace Therapeutics, a biopharmaceutical company that develops innovative drug delivery technologies for rare and orphan diseases. Upon completion of the acquisition, Acasti will acquire Grace’s pipeline of drug candidates addressing critical unfulfilled medical needs, and the potential to deliver significant value to patients and providers.

Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids.

The Osler, Hoskin & Harcourt team consisted of François Paradis (Picture), Jason Comerford and Matthew Oliver (Corporate), Paul Seraganian, Manon Thivierge and Kaleigh Hawkins-Schulz (Taxation).

The Reed Smith team was comprised of partners Jennifer Cheng and Niket Rele, counsel Sue Nieto, and associates Doug Sayranian and Sheran Sharafi.

Involved fees earner: Jason Comerford – Osler Hoskin & Harcourt; Kaleigh Hawkins-Schulz – Osler Hoskin & Harcourt; Matthew Oliver – Osler Hoskin & Harcourt; Francois Paradis – Osler Hoskin & Harcourt; Paul Seraganian – Osler Hoskin & Harcourt; Manon Thivierge – Osler Hoskin & Harcourt; Jennifer Cheng – Reed Smith; Susan Nieto – Reed Smith; Niket Rele – Reed Smith; Douglas Sayranian – Reed Smith; Sheran Sharafi – Reed Smith;

Law Firms: Osler Hoskin & Harcourt; Reed Smith;

Clients: Acasti Pharma; Grace Therapeutics;

Author: Martina Bellini